Giuseppe Papa

Dr. Giuseppe Papa

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
GPGiuseppe Papa
Giuseppe Papa
CDClaudia Degano
Claudia Degano
MIMaria P Iurato
Maria P Iurato
CLCarmelo Licciardello
Carmelo Licciardello
RMRaffaella Maiorana
Raffaella Maiorana
CFConcetta Finocchiaro
Concetta Finocchiaro
Macrovascular diseases (MVD) in type 2 diabetes mellitus (T2DM) are often considered all together, without discriminating the areas involved. The aim of our study was to analyse MVD prevalence in a large population of T2DM patients by dividing the cases into subgroups according to MVD sites (NMVD, no MVD; NSCS, non-significant carotid stenosis; CBVD, cerebrovascular disease; CAD, coronary artery disease; PAD, peripheral artery disease; PVD, polyvascular disease) and studying the anthropometric, clinical and laboratory parameters in each group.

25 January 2012 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
GPGiuseppe Papa
Giuseppe Papa
RBRoberto Baratta
Roberto Baratta
VCVincenzo Calì
Vincenzo Calì
CDClaudia Degano
Claudia Degano
MIMaria Pierangela Iurato
Maria Pierangela Iurato
CFConcetta Finocchiaro
Concetta Finocchiaro

17 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
CGCarmelo Gusmano
Carmelo Gusmano
Rossella CannarellaRossella Cannarella
Rossella Cannarella
CFConcetta Finocchiaro
Concetta Finocchiaro
GGGianfranco Gruttadauria
Gianfranco Gruttadauria
RRRosario Randazzo
Rosario Randazzo
GPGiuseppe Papa
Giuseppe Papa
Background and Aims: Automated insulin delivery (AID) systems are standard of care for type 1 diabetes mellitus (T1DM). Tubeless AID systems may improve treatment acceptance, but real-world European data in patients transitioning from multiple daily injections (MDI) or open-loop patch pump therapy are limited. This study evaluated real-world glycemic, safety, and quality-of-life (QoL) outcomes after transition to a tubeless automated closed-loop system (Omnipod 5®, OP5®). Research Design and Methods: In this prospective, multicenter observational study, adults with T1DM transitioned from MDI or open-loop continuous subcutaneous insulin infusion to OP5® and were followed for 180 days. Continuous glucose monitoring-derived metrics and validated patient-reported outcome measures were assessed. Subgroup analyses were performed by prior therapy. Results: Of the 94 enrolled participants, 88 completed the study. At 180 days, HbA1c decreased from 7.5% to 7.1% (p < 0.001), and time in range increased from 59.0% to 68.0% (p < 0.001) without increased hypoglycemia. The proportion achieving TIR70–180 ≥ 70% rose from 12.5% to 43.2%. Improvements were greater among prior MDI users. Treatment satisfaction and diabetes-related QoL improved significantly. The mean time in automated mode was 90.9%. Conclusions. Transition to tubeless AID significantly improved glycemic and psychosocial outcomes, supporting its effectiveness in routine clinical practice.

14 October 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
ATAndrea Tumminia
Andrea Tumminia
GPGiuseppe Papa
Giuseppe Papa
RCRossella Cannarella
Rossella Cannarella
FGFrancesco Galeano
Francesco Galeano
VOVittorio Oteri
Vittorio Oteri
Aldo E. CalogeroAldo E. Calogero
Aldo E. Calogero

29 October 2026 in Endocrine
Verified
Journal Article
Open access
PDF file
FGFrancesco Galeano
Francesco Galeano
AMAgnese Rita Catena Mobilia
Agnese Rita Catena Mobilia
Filippo Luca FimognariFilippo Luca Fimognari
Filippo Luca Fimognari
Vittorio OteriVittorio Oteri
Vittorio Oteri
Rossella CannarellaRossella Cannarella
Rossella Cannarella
ATAndrea Tumminia
Andrea Tumminia
Objective: Automated insulin delivery (AID) systems have significantly improved the management of type 1 diabetes (T1D), leading to better glycemic control and reduced hypoglycemia. However, older adults (≥ 65 years) remain underrepresented in clinical trials, and evidence specific to this population is limited. Design and patients: This narrative review synthesizes current evidence on the efficacy, safety, and usability of AID systems in older adults (≥ 65 years) with T1D. A comprehensive literature search of MEDLINE/PubMed was conducted using the PICO framework to identify relevant RCTs, observational studies, and systematic reviews, supplemented by literature studies on cognitive, functional, and psychosocial factors impacting technology adoption. Results: While data from randomized trials and meta-analyses in the general population consistently demonstrate improvements in time in range (TIR, 70–180 mg/dL) and reductions in hypoglycemia, evidence in older adults is still emerging. Frail individuals and those with multiple comorbidities are often underrepresented or excluded from current studies. Nevertheless, the available evidence suggests that many of these benefits are also maintained in older populations, particularly regarding hypoglycemia reduction. At the same time, factors such as cognitive impairment, functional limitations, caregiver dependence, and reduced digital literacy may affect the adoption and effective use of these technologies. Conclusions: AID systems appear effective and generally safe in selected older adults, with benefits in glycemic control and hypoglycemia reduction. However, given the marked heterogeneity of this population, further studies are needed to better define their role and applicability in routine clinical practice.

30 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Sandro La VigneraSandro La Vignera
Sandro La Vignera
Aldo E. CalogeroAldo E. Calogero
Aldo E. Calogero
Rossella CannarellaRossella Cannarella
Rossella Cannarella
ACAndrea Crafa
Andrea Crafa
FBFederica Barbagallo
Federica Barbagallo
RCRosita Angela Condorelli
Rosita Angela Condorelli
Background/Objectives: Diabetes management technologies—including continuous glucose monitors (CGM), insulin pumps (CSII), advanced hybrid closed-loop (AHCL) systems, and mobile health applications—have transformed diabetes care, yet gender-specific differences in ad-herence, clinical outcomes, and patient-reported outcomes remain inadequately char-acterised. Methods: We conducted a systematic literature review following PRISMA 2020 guide-lines, searching SciSpace, Google Scholar, and PubMed databases. From 852 identified records, 500 underwent title/abstract screening after duplicate removal; 16 studies were ultimately included in the qualitative synthesis. Results: Included studies examined insu-lin pumps (n = 7), CGM (n = 6), AHCL systems (n = 4), remote monitoring programmes (n = 2), and mobile health applications (n = 1); sample sizes ranged from 72 to 22,697 participants. In predominantly paediatric evidence, females demonstrated higher insu-lin pump discontinuation rates (discontinuation groups: 75% vs. 46%, p = 0.001), driv-en by body image concerns and device visibility (data from a single small predomi-nantly paediatric cohort; group sex compositions, not absolute discontinuation rates), whereas in a single small adult cohort (n = 72), males showed poorer adherence to in-termittently scanned CGM (approximately four fewer scans/day, p = 0.011). Glycaemic outcomes were modestly but consistently different: males achieved slightly higher time-in-range while females exhibited lower glycaemic variability; menstrual cycle effects on glycaemic control were partially mitigated by AHCL systems. Females con-sistently reported greater diabetes-related distress and a more negative perception of glycaemic control despite similar or better objective metrics. Conclusions: In conclusion, sex-based and gender-related differences are apparent across technology type, adherence, gly-caemic control, and psychosocial outcomes—albeit from a limited evidence base re-quiring cautious interpretation; sex-sensitive prescription, education, and technology design are warranted. Note: most included studies reported biological sex (male/female) rather than self-identified gender; conclusions should be interpreted primarily as sex-based differences.